As of June 7, 2025, United Therapeutics Corp (UTHR) reports a EV/EBITDA of 8.73.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing United Therapeutics Corp's EV/EBITDA to Peers
To better understand United Therapeutics Corp's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| United Therapeutics Corp (UTHR) | 8.73 |
| TG Therapeutics Inc (TGTX) | 91.92 |
| Amicus Therapeutics Inc (FOLD) | 43.02 |
| Abbvie Inc (ABBV) | 18.25 |
| Amgen Inc (AMGN) | 15.22 |
| Regeneron Pharmaceuticals Inc (REGN) | 14.93 |
Compared to its competitors, United Therapeutics Corp's EV/EBITDA is among the highest compared to peers, suggesting the market values the company at a premium, possibly due to growth expectations.